US0373261058
US0373261058
AN2 Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 166.04M EUR | 175.73M EUR | 123.07M EUR | 31.25M EUR |
Enterprise Value | 98.22M EUR | 131.42M EUR | 69.58M EUR | 11.31M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -5.5x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 2.1x | 2.31x | 1.51x | 0.59x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -- | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -10.85% | -17.46% | -25.42% | -61.47% |